Shibuya

Promethera Biosciences and Shibuya Announce Strategic Collaboration to Establish Breakthrough Cell Therapy Manufacturing Platform

Mont-Saint-Guibert, Belgium, and Kanazawa, Ishikawa, Japan October 5, 2017 –Promethera Biosciences SA, a global innovator in cell-based medicines, and Shibuya Corporation (6340:Tokyo Stock Exchange) announced today a strategic collaboration to establish a high-throughput, commercial-scale and clinical-grade cell therapy and regenerative medicine manufacturing platform.